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Dollars). RESULTS: Cancer-related CRC costs averaged $32,303
in the initial phase, $3,548 per year in the continuing phase, and
$14,323 in the terminal phase. Initial-phase costs were similar by
site (CC: $32,528; RC: $31,701; P = 0.015), while continuing-
phase costs were roughly 1/3 higher for RC versus CC ($4,266
vs. $3,287; P < 0.001). Terminal-phase costs were $14,197
for CC and $14,654 for RC (P = 0.424). Initial-phase CC costs
were $17,278 and $40,501 for Stages 0 and 4, respectively
(P < 0.001), compared to $14,060 and $37,235 for Stage 0 and
4 RC (P < 0.001). Continuing costs ranged from $2,499–
$17,861 and $2,822–$17,741 for Stage 0–4 CC and RC patients,
respectively; terminal costs ranged from $7,814–$27,742 for
Stages 0–4 CC and $6,376–$20,047 for Stages 0–4 RC patients.
CONCLUSION: Excess costs associated with CRC are striking
and vary considerably by treatment phase, cancer site, and stage
at diagnosis. Interventions aimed at earlier diagnosis and preven-
tion have the potential to reduce cancer-related health care costs.
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OBJECTIVE: To determine how independent variables (e.g.,
gender, comorbidities, etc) predict total medical cost of lung
cancer in the two years following dignosis after we account for
the bias introduced by censoring. METHODS: Since health care
costs and utilization may be subject to right censoring and there-
fore are not always observable, the standard regression models
cannot be used to assess the effects of confounders. Inverse
Probability Weighted estimation is ideally suited to estimation
from non-random samples which might arise due to censoring or
by the censoring strategy used. IPW produces consistent estima-
tor with a covariance matrix that can be calculated by most
commercial statistics software. We applied a test to see if possible
censoring bias exists. We also calculated the deviation from the
consistent value if standard ordinary least square method was
used. RESULTS: A total of 201 patients with incident of cases of
lung were recruited from Michigan community hospitals and
their oncology units. We obtained Medicare claim ﬁles for the
two years following diagnosis. 28.8 percent of the cases were
censored, therefore their annual costs were not observed. The
total cost of all care is $60,429 for the two years following a
lung-cancer diagnosis and $55,877 for incomplete cases. Inverse
probability weighted results signiﬁcantly diverged from standard
regression model. There exist a selection bias (p = 0.000) there-
fore IPW estimation yielded consistent results. CONCLUSION:
This paper applies the inverse probability weighted estimation to
an inception cohort of patients newly diagnosed with lung
cancer. Our ﬁndings suggest that standard regression models
yields inconsistent estimator due to censoring bias. IPW least
square estimation method removes that bias.
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OBJECTIVE: Cervical cancer is the top female cancer in terms of
incidence rate in Taiwan. Since July 1, 1995, the NHI program
has provided annual cervical smear tests for all women over the
age of 30. Besides, the vaccine for preventing cervical cancer has
been marketed in Taiwan in 2006. The purpose of this paper was
to estimate the lifetime (20 years) direct medical cost of cervical
cancer patients for future economic evaluation. METHODS: The
estimation of the lifetime cost based on insurer perspective and
incidence approach sourced from 1994–2002 cancer registry sta-
tistics of patients with cervical cancer and the claim data from
Taipei Veterans General Hospital (TPE-VGH). Totally, we have
2525 patients. Propensity score method was applied to match the
comparison group using the population claimed data from The
National Health Research Institutes (NHRI). The probabilities of
survival, dying of cancer or dying of other causes were estimated
through Cancer Registry statistics. We divided the whole disease
process into initial, continuing and terminal three phases. The
cost of cancer is the sum of the average cost of each phase.
Lifetime costs of cancers were estimated from the costs calculated
above incorporate survival rates of the cancers. RESULTS: The
results showed only 61 patients survived less than one year and
each patient spent US$13,358 during that period. For those
survived more than one year, terminal phase resulted in the
highest costs which was US$23,078. For those survived more
than one year, the initial phase cost for each patient was
US$4157 and the monthly cost for continuing phase was
US$113. The expected lifetime cost (20 years) of average cervical
cancer patient was US$30,238. CONCLUSION: Our study
provided critical information for the economic evaluation of
Pap smears screening and the vaccination program for human
papilloma virus.
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OBJECTIVE: Currently, two out of every 100,000 people
develop Chronic Lymphocytic Leukemia (CLL) annually. Over
90% of cases are found in people who are older than 50 years
of age. As the United States population ages over the next
two decades signiﬁcantly more patients with CLL are likely
to be diagnosed resulting in increased spending on CLL.
METHODS: Prevalence estimates of CLL in various age
cohorts from Surveillance Epidemiology and EndResults
(SEER) data combined with population demographics from the
United States Census Bureau are used to project the direct costs
associated with CLL over the next two decades. Sensitivity
analysis is conducted around all estimates to assess key model
parameters. RESULTS: In 2006, the average direct cost of
treatment was estimated at $304 million this is estimated to
increase to 333 million by 2010 and over 413 million in 2020;
an increase of 27% in the numbers of individuals in need of
treatment. These conservative cost estimates are based on
changing demographic distributions and do not include
increases in the costs of health care delivery, treatments or indi-
rect costs. The total costs of CLL are expected to reach over
1.5 billion USD by the year 2020. CONCLUSION: This work
reviews the literature on the economic costs associated with
CLL and based on expected demographic changes to the United
States population, identiﬁes an area of increasing concern to
health care policy makers and providers of clinical services to
oncology patients.
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